Achieve Life Sciences, Inc. ACHV Cash Flow

Achieve life sciences, inc. (ACHV)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Operating Activities:
Net loss
-13,811	-16,395	-16,838	-16,405	-15,569	-12,687	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-15,799	-19,691	-20,129	-16,010	-16,870	-15,991	-16,801	-20,758	-21,116	-22,121	-26,240	-27,237	-32,383	-33,788	-31,849	-29,274	-25,140	-20,935	-21,098	-36,772	-35,323	-18,488	-14,673	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization [note 3]
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on warrants [note 7 and note 11[e]]
-	-	-	-	-	-	-	-	-	-150	-229	-857	-258	-873	-2,486	-1,996	-2,099	-1,897	-1,139	-3,882	-4,927	-3,741	-3,102	-767	-1,053	-3,208	-4,811	-6,580	-7,323	-4,459	0	0	0	-	-	-	-
Depreciation
-	-	-	-	-	-	-	-	-	-	-	215	225	188	214	231	254	244	236	229	214	223	230	237	238	227	191	157	125	100	0	0	0	-	-	-	0
Stock-based compensation [note 6 [c] and note 6 [d]]
1,213	1,201	1,183	1,083	963	854	784	303	318	348	548	685	1,392	1,649	1,641	2,487	2,280	2,328	2,832	3,072	3,376	3,860	3,312	3,247	3,086	2,834	3,055	2,749	2,603	2,175	1,932	1,663	1,237	1,188	0	0	0
Restructuring gain [note 8]
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Interest receivable
-	-	-	-	-	-	-	-	-	-	-	-47	-53	-79	-12	-29	-18	-2	29	76	-95	-105	-276	-300	-155	-109	-212	-172	-51	-36	0	0	0	-	-	-	-
Gain on warrants [notes 4 and 5]
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Amounts receivable
0	-	-	-	-	-	-	-	-	9	484	-66	4	464	145	158	-1,326	-5,662	-4,814	-4,802	-7,051	-2,981	-5,095	-1,488	3,454	7,943	9,291	5,955	4,754	265	218	-440	-372	-201	0	0	0
Prepaid expenses and other assets
83	-195	-42	266	472	343	-460	1,563	1,321	1,349	904	-990	-845	-1,057	23	-1,039	-2,410	-1,167	-1,852	-1,467	883	-3,944	-653	-1,205	-1,641	1,974	0	0	0	-	-	-	-	-	-	-	-
Prepaid expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0
Accounts payable
-510	715	116	456	274	-69	-37	2,044	2,087	118	1,478	-326	-233	778	-736	257	-396	1,271	217	-1,039	65	-67	1,523	1,211	-276	-1,190	0	0	0	-	-	-	-	-	-	-	-
Accrued liabilities other
-259	-328	-327	-620	17	310	-745	-378	-581	-2,185	717	541	23	1,801	1,791	1,668	1,895	-222	-1,918	-3,011	-2,743	363	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accrued clinical liabilities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued clinical liabilities
-	-	-	-	-	-	-	0	3,847	-	-3,537	-7,653	-8,108	-6,551	-3,072	-2,993	-1,433	-3,714	0	0	0	-	-	-	-	7,563	0	0	0	-	-	-	-	-	-	-	-
Accrued compensation
0	-	0	0	0	-	0	0	570	-	-1,919	-1,074	-534	-1,079	-188	76	13	-66	501	271	-173	-372	-248	-156	211	164	0	0	0	-	-	-	-	-	-	-	-
Other liabilities
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21	-29	-61	-61	-63	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Excess lease liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-194	-397	-596	-790	-785	-758	-732	-705	-680	0	0	0	-	-	-	-	-	-	-	-
Accounts payable and accrued liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0
Excess lease liability [note 6]
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0
Lease obligation [note 7]
0	-	-	-	0	-	-	-	-	-27	-29	73	56	51	46	43	38	-100	-96	-94	-70	84	73	62	54	21	0	0	0	-	-	-	-	-	-	-	-
Proceeds from the exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	30	30	30	30	10	0	0	0	-	-	-	-	-	-	-	-
Net cash used in operating activities
-14,788	-15,216	-15,343	-15,252	-13,279	-10,623	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-38,436	-31,693	-23,603	-20,263	0	0	0
Financing Activities:
Proceeds from purchase agreement with Lincoln Park Capital, net of issuance costs
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred collaboration revenue [note 3]
-	-	-	-	-	-	-	-	-	-	-	-	-	-5,040	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-18,271	-9,891	-4,495	-3,706	-3,351	0	0	0
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-25,768	-29,591	-29,683	-33,389	-34,758	-11,744	-9,101	-5,360	-2,488	-22,060	-17,308	-17,902	-22,373	-26,928	-35,927	0	0	0	-	-	-	-	-	-	-	-
Taxes paid related to net share settlement of equity awards
-	-	-	-	-	-	-	-	-	5	0	0	0	-	-	-	-	52	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of investments
-	-	-	-	-	-	-	-	-	-	-	7,397	12,340	36,504	35,551	51,454	49,608	24,368	37,109	21,256	18,324	19,446	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	0
Issuance of common shares, net of share issue costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-
Net cash used in financing activities
0	-	-	-	-	19,757	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	54,243	54,019	53,907	219	0	0	0
Investing Activities:
Purchase of investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	57,745	66,206	80,013	110,443	98,870	105,227	88,243	75,147	0	0	0
Proceeds from sale of investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-11,698	20,219	12,656	0	0	0
Proceeds from maturities of investments
-	-	-	-	-	-	-	-	-	-	-	36,534	38,774	47,158	38,358	34,505	36,507	21,659	17,707	8,061	12,147	24,894	33,125	39,090	59,506	63,375	0	0	0	-	-	-	-	-	-	-	-
Purchase of property and equipment
1	53	0	0	0	-	-	-	-	-	-	0	0	-	-	-	-	371	303	280	280	82	99	95	150	253	0	0	0	-	-	-	-	79	0	0	0
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	17,591	17,590	22,344	25,165	25,247	25,234	6,064	30	10	0	0	0	-	-	-	-	-	-	-	-
Proceeds on disposal of assets
-	-	-	-	-	10	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of investments
-	25	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from maturities of investments
-	5,114	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	29,125	26,387	10,608	2,698	-17,090	-12,264	-2,077	-18,702	-12,472	-6,457	5,366	28,666	38,149	36,889	32,426	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by (used in) investing activities
2,344	5,036	1,328	-62	-2,445	-5,125	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-20,202	-29,387	19,567	25,068	0	0	0
Effect of exchange rate changes on cash
2	4	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash
-	-	-	-	-	-	-	-	-4	-	0	0	0	-	-	-	-	-	-	-	-	-	-	25	11	9	0	0	0	-	34	27	-17	-40	0	0	0
Net increase (decrease) in cash, cash equivalents and restricted cash
4,836	7,149	-4,380	-4,834	2,933	4,009	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	3,335	-3,223	-19,077	-30,677	-37,420	-6,365	6,413	-6,473	7,387	-3,352	13,304	36,000	21,865	10,002	-3,482	1,588	4,907	-38,224	-10,442	-4,361	-7,034	49,854	4,984	0	0	0
Property and equipment acquired under lease obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	89	0	0	0
December 2019 Registered Direct Offering [Member]
Costs relating to registered direct offering and purchase agreement
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-